Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of CONFIDENCE Randomized Trial

Journal:

Journal of the American College of Cardiology

Published:

2025-11-09

DOI:

10.1016/j.jacc.2025.10.049

Affiliations:

17

Authors:

15

Go to article

Institutions	Authors	Share
Bayer, Germany	2.000000	0.13
Bayer U.S., United States of America (USA)	2.000000	0.13
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), United States of America (USA)	1.000000	0.07
Velocity Clinical Research, United States of America (USA)	1.000000	0.07
Brigham and Women's Hospital (BWH), United States of America (USA)	1.000000	0.07
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.07
University of Erlangen-Nuremberg (FAU), Germany	1.000000	0.07
Duke University Health System, United States of America (USA)	1.000000	0.07
University Medical Center Groningen (UMCG), RUG, Netherlands	1.000000	0.07
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	1.000000	0.07
The University of Tokyo (UTokyo), Japan	1.000000	0.07
Steno Diabetes Center Copenhagen (SDCC), Denmark	0.500000	0.03
University of Copenhagen (UCPH), Denmark	0.500000	0.03
Richard L. Roudebush VA Medical Center, United States of America (USA)	0.500000	0.03
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?